Vor Biopharma VOR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$219.59M— | —— | -$812.68M+48.4% | -$1.57B-4,744% | -$32.49M-5.8% | ||
| $28K+21.7% | $23K+1,050% | $2K-99.9% | $2.1M+155% | $825K-4.6% | ||
| $8.87M+24.8% | $7.11M-11.5% | $8.03M+335% | $1.84M-4.6% | $1.93M+13.1% | ||
| -$0— | —— | —— | -$3.3M-329,900% | -$1K-106% | ||
| -$9.1M-247% | $6.21M+24.1% | $5M+356% | $1.1M+180% | -$1.37M-137% | ||
| $6.36M— | —— | —— | -$2.86M-1,339% | $231K— | ||
| -$61K-3.4% | -$59K-195% | -$20K+98.4% | -$1.28M-22.0% | -$1.05M-2.3% | ||
| -$38.25M-67.7% | -$22.8M+57.5% | -$53.66M-52.5% | -$35.18M-13.3% | -$31.07M-29.1% | ||
| $48K-84.7% | $314K+28.7% | $244K+60.5% | $152K-34.2% | $231K+221% | ||
| -$263.24M-438% | -$48.97M-19,971% | -$244K-138% | $646K+381% | -$230K— | ||
| $2K-98.6% | $148K+679% | $19K-40.6% | $32K-41.8% | $55K+83.3% | ||
| $74.87M-75.7% | $307.8M+1,328% | $21.55M-87.7% | $175.07M+28,989% | -$606K-101% | ||
| -$226.61M-196% | $236.02M— | —— | $140.53M+540% | -$31.9M-209% | ||
| $28K+21.7% | $23K+1,050% | $2K-99.9% | $2.1M+155% | $825K-4.6% | ||
| -$61K-3.4% | -$59K-195% | -$20K+98.4% | -$1.28M-22.0% | -$1.05M-2.3% | ||
| $20K-99.1% | $2.11M+1,500% | -$151K+92.3% | -$1.95M-13,821% | -$14K+89.1% | ||
| $6.36M— | —— | —— | -$2.86M-1,339% | $231K— | ||
| —— | $331.25K0.0% | $331.25K0.0% | $331.25K0.0% | $331.25K-43.0% | ||
| $127K— | —— | $643K— | —— | $551K— | ||
| —— | $27.03M0.0% | $27.03M0.0% | $27.03M0.0% | $27.03M— | ||
| $75M— | —— | —— | —— | $0-100% | ||
| $12K— | —— | —— | —— | $0— | ||
| $188.36M— | —— | $790.46M-39.2% | $1.3B— | $0— | ||
| -$61K-3.4% | -$59K-195% | -$20K+98.4% | -$1.28M-22.0% | -$1.05M-2.3% | ||
| $93K— | —— | —— | —— | $0— | ||
| —— | $44.34M0.0% | $44.34M0.0% | $44.34M0.0% | $44.34M— | ||
| $109K+1.9% | $107K+78.3% | $60K-98.6% | $4.17M+218% | $1.31M+1.6% | ||
| -$38.29M-65.7% | -$23.12M+57.1% | -$53.91M-52.6% | -$35.34M-12.9% | -$31.3M-29.7% | ||
| -$38.29M-65.7% | -$23.12M+57.1% | -$53.91M-52.6% | -$35.34M-12.9% | -$31.3M-29.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vor Biopharma generate?
- Vor Biopharma (VOR) generated -$149.9M in operating cash flow over the trailing twelve months.
- What is Vor Biopharma's free cash flow?
- After $758.0K of capital expenditures, Vor Biopharma's free cash flow was -$150.7M over the trailing twelve months, down 49.7% year over year.
- Where does Vor Biopharma's cash flow data come from?
- Every line is extracted from Vor Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.